ウシ胎児血清の市場規模：用途、エンドユーザー、地域別、2024年～2031年

ウシ胎児血清市場の評価、2024年～2031年

ウシ胎児血清（FBS）の需要増が市場の成長を大きく後押ししています。FBSは、バイオ医薬品の開発やワクチン製造に不可欠な細胞培養や組織工学の用途をサポートする上で、不可欠な役割を果たすことが広く認識されています。こうした需要の急増により、2024年の市場規模は9億4,449万米ドルを超え、2031年には213億7,480万米ドルに達する見通しです。

FBSはまた、細胞の成長と増殖を促進する豊富な栄養成分で評価されており、研究所や研究機関で好んで使用されています。再生医療や個別化治療におけるその重要性は、さらにその使用量の増加に寄与しています。ウシ胎児血清市場は、2024年から2031年までCAGR5.30％で成長すると予想されています。

ウシ胎児血清市場定義/概要

ウシ胎児血清は、牛の胎児の血液から得られる栄養豊富な製品別であり、バイオテクノロジーや製薬研究で一般的に使用されています。細胞の成長と維持に必要な必須栄養素、成長因子、ホルモンを多く含むため、細胞培養アプリケーションにおいて重要な役割を果たしています。FBSは、ワクチン、組換えタンパク質、モノクローナル抗体の開発のためのバイオ医薬品製造に広く利用されています。がん研究、遺伝子工学、組織工学、幹細胞研究などの研究開発にも欠かせないです。

ウシ胎児血清の将来は、製薬業界やバイオテクノロジー業界からの需要の増加に牽引され、有望視されています。倫理的な懸念、サプライチェーンの制約、無血清あるいは合成血清の代替品開発への注目の高まりが、その軌道を形成するかもしれないです。業界の進化に伴い、動物細胞を含まない細胞培養培地の採用が勢いを増しており、長期的にはFBSへの依存度を低下させる可能性があります。

幹細胞および再生医療研究の成長は、ウシ胎児血清の需要をどのように促進するか？

米国研究製薬工業協会（PhRMA）によると、バイオ医薬品業界は2021年に約1,023億米ドルを研究開発に投資し、2020年から7.4％増加しました。この成長は、FBSのような細胞培養培地やサプリメントの需要に直接影響します。幹細胞と再生医療研究の成長は、細胞培養と組織工学におけるその重要な役割により、ウシ胎児血清（FBS）の需要を大きく牽引しています。FBSは必須栄養素、成長因子、ホルモンを豊富に含んでおり、実験室での幹細胞の成長、分化、増殖をサポートする理想的な培地となっています。損傷した組織や臓器の修復や置換を目的とする再生医療では、FBSは研究や治療応用のための幹細胞の培養に広く使用されています。

パーキンソン病、アルツハイマー病、心血管疾患などの変性疾患に対する新規治療法の開発にますます注目が集まっているため、FBSのような高品質の細胞培養培地の必要性が高まっています。さらに、研究者が幹細胞治療の効率と安全性の向上に取り組む中、信頼性が高く安定したFBSの供給源に対する需要が急増しています。再生医療の分野が拡大するにつれ、細胞の成長と技術革新に最適な環境を提供するFBSへの信頼も高まり、FBS市場全体の成長に寄与しています。

ウシ胎児血清（FBS）の使用に関する倫理的懸念は、その需要と将来の市場成長にどのように影響するか？

ウシ胎児血清（FBS）の使用に関する倫理的懸念は、ウシの胎児から血液を採取するというその抽出方法のために、その需要と市場成長に大きく影響します。多くの動物愛護団体や研究者が、FBSの使用は動物に不必要な危害を及ぼすとして倫理的な反対を表明しています。このため、製薬会社やバイオテクノロジー企業に対し、合成培地や植物由来の培地など、より人道的な代替手段を細胞培養に採用するよう求める圧力が高まっています。

倫理的意識が世界的に高まるにつれ、研究機関や企業は、こうした論争を避けるため、動物を使わない培地を含む代替方法を模索しています。さらに、地域によっては動物由来製品の使用に対してより厳しい規制を課しており、FBSに依存している企業にとってはコンプライアンスの複雑さが増しています。この倫理的議論は、多くの研究者に、より持続可能な手法への転換を促しただけでなく、細胞に同様の増殖条件を提供できる合成代替品の開発を誘発しました。その結果、こうした懸念は将来的にFBS市場の成長を鈍化させる可能性が高く、企業は革新的な代替ソリューションを採用する必要に迫られています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 ウシ胎児血清市場：用途別

• バイオ医薬品産業
• 学術・研究施設
• 細胞療法と組織工学

第5章 ウシ胎児血清市場：エンドユーザー別

• 商社
• 開発業務受託機関（CRO）
• 学術・研究施設

第6章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第7章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第8章 競合情勢

• 主要企業
• 市場シェア分析

第9章 企業プロファイル

• Thermo Fisher Scientific
• Merck KGaA
• GE Healthcare
• Atlanta Biologicals
• Bovogen Biologicals
• PAN-Biotech
• Biological Industries
• Corning Life Sciences
• Wisent Inc.
• RMBIO

第10章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第11章 市場展望付録

• 略語リスト
• 出典と参考文献

Fetal Bovine Serum Market Valuation - 2024-2031

The increasing demand for fetal bovine serum (FBS) has significantly propelled the market's growth. FBS is widely recognized for its essential role in supporting cell culture and tissue engineering applications, which are crucial for biopharmaceutical development and vaccine production. This surge in demand has led to the market size exceeding USD 944.49 Million in 2024, with projections indicating it could reach a valuation of USD 21374.8 Million by 2031.

FBS is also valued for its rich nutrient composition, which enhances cell growth and proliferation, making it a preferred choice in laboratories and research institutions. Its importance in regenerative medicine and personalized therapy further contributes to its rising usage. The fetal bovine serum market is expected to grow at a compound annual growth rate (CAGR) of 5.30% from 2024 to 2031.

Fetal Bovine Serum Market: Definition/ Overview

Fetal Bovine Serum is a nutrient-rich byproduct derived from the blood of cow fetuses, commonly used in biotechnology and pharmaceutical research. It plays a critical role in cell culture applications due to its high content of essential nutrients, growth factors, and hormones needed for cell growth and maintenance. FBS is widely utilized in biopharmaceutical production for the development of vaccines, recombinant proteins, and monoclonal antibodies. It is vital in research and development for cancer research, genetic engineering, tissue engineering, and stem cell studies.

The future of the Fetal Bovine Serum looks promising, driven by increasing demand from the pharmaceutical and biotech industries. Ethical concerns, supply chain constraints, and the rising focus on developing serum-free or synthetic alternatives may shape its trajectory. As the industry evolves, the adoption of animal-free cell culture media is gaining momentum, potentially decreasing reliance on FBS in the long run.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Does the Growth in Stem Cell and Regenerative Medicine Research Drive the Demand for Fetal Bovine Serum?

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry invested approximately $102.3 billion in R&D in 2021, marking a 7.4% increase from 2020. This growth directly impacts the demand for cell culture media and supplements like FBS. The growth in stem cell and regenerative medicine research significantly drives the demand for fetal bovine serum (FBS) due to its critical role in cell culture and tissue engineering. FBS is rich in essential nutrients, growth factors, and hormones, making it an ideal medium for supporting the growth, differentiation, and proliferation of stem cells in laboratory settings. In regenerative medicine, where the goal is to repair or replace damaged tissues and organs, FBS is extensively used to culture stem cells for research and therapeutic applications.

The increasing focus on developing novel therapies for degenerative diseases, such as Parkinson's, Alzheimer's, and cardiovascular conditions, has heightened the need for high-quality cell culture media like FBS. Additionally, as researchers work on improving the efficiency and safety of stem cell therapies, the demand for reliable and consistent sources of FBS has surged. As the field of regenerative medicine expands, so does the reliance on FBS to provide an optimal environment for cell growth and innovation, thereby contributing to the overall growth of the FBS market.

How Do Ethical Concerns Regarding the Use of Fetal Bovine Serum (FBS) Impact Its Demand and Future Market Growth?

Ethical concerns regarding the use of fetal bovine serum (FBS) significantly impact its demand and market growth due to the method of its extraction, which involves harvesting blood from bovine fetuses. Many animal rights organizations and researchers have raised ethical objections to the practice, arguing that it causes unnecessary harm to animals. This has led to growing pressure on pharmaceutical and biotechnology companies to adopt more humane alternatives for cell culture, such as synthetic or plant-based media.

As ethical awareness increases globally, research institutions and businesses are exploring alternative methods, including animal-free media, to avoid these controversies. Furthermore, some regions have imposed stricter regulations on the use of animal-derived products, increasing the complexity of compliance for companies relying on FBS. This ethical debate has not only prompted many researchers to shift toward more sustainable practices but has also triggered the development of synthetic alternatives that can provide similar growth conditions for cells. As a result, these concerns are likely to slow the growth of the FBS market in the future, pushing companies to innovate and adopt alternative solutions.

Category-wise Acumens

What Factors are Driving the Increasing Demand for Fetal Bovine Serum in Academic & Research Facilities Segment?

The academic & research facilities significant stand out as a significant segment in the Fetal Bovine Serum (FBS) market, driven by the growing demand for high-quality serum in various scientific studies. FBS is widely used in cell culture applications, playing a crucial role in the growth and maintenance of cells in research involving immunology, cancer, drug development, and toxicology. The increasing focus on advancements in life sciences research, particularly in areas like stem cell research and biotechnology, has fueled the demand for FBS in academic institutions and research laboratories.

The research facilities rely on FBS for its high content of growth factors, which are essential for supporting cell viability in experimental settings. The rising number of clinical trials, coupled with the need for reliable serum to maintain reproducibility in experiments, contributes to the growth of this segment. As academic and research institutions continue to push the boundaries of scientific discovery, the demand for FBS is expected to remain strong, positioning Academic & Research Facilities as a key segment in the FBS market.

How Do Contract Research Organizations (Cros) Contribute to the Growth of the Fetal Bovine Serum Market?

The contract research organizations (CROs) segment stands out as a significant segment in the Fetal Bovine Serum (FBS) market, contributing to its growth by providing essential services such as clinical trials, product testing, and drug development. CROs play a vital role in the biotechnology and pharmaceutical industries by outsourcing research and development processes, which helps companies expedite their innovation pipelines. Their involvement in cell culture studies, vaccine development, and stem cell research drives the demand for high-quality FBS, which is essential for these applications.

The reliance on CROs for conducting large-scale clinical trials and regulatory testing is especially prominent in developing markets, where companies seek to minimize costs and access expertise in specialized areas. As the demand for biopharmaceutical products and regenerative medicine continues to rise, CROs' need for reliable, consistent sources of FBS grows in parallel. This segment's expanding role, particularly in preclinical and clinical research, further solidifies CROs' contribution to the overall growth of the FBS market, making them a key driver of its ongoing development.

Fetal Bovine Serum

Market Report Methodology

Country/Region-wise Acumens

What Are the Key Factors Driving the Growth of the Fetal Bovine Serum (FBS) Market in the North American region?

North America significantly dominates the fetal bovine serum market and is expected to maintain this position throughout the forecast period, driven by a robust biopharmaceutical industry and extensive research activities in academic and research facilities. The FDA approved 22 cell and gene therapy products as of 2023, with over 1,000 active Investigational New Drug (IND) applications for ongoing clinical studies in cell and gene therapies. The American Society of Gene & Cell Therapy reports that the number of clinical trials utilizing cell and gene therapies has grown by an average of 32% annually since 2016. The region is home to numerous biotechnology and pharmaceutical companies that utilize FBS in the production of vaccines, therapeutic proteins, and various cell culture applications, significantly boosting demand.

The increasing investment in research and development within the academic sector, along with collaborations between universities and commercial firms, further propels the growth of the FBS market. The growing trend of cell therapy and tissue engineering, where FBS is often used as a supplement in cell culture, adds to the market dynamics. Moreover, stringent quality standards and regulations in North America ensure high-quality products, reinforcing consumer trust. The emphasis on innovation and the development of advanced technologies in the biopharmaceutical field, coupled with the increasing prevalence of chronic diseases, are expected to further fuel the demand for FBS in the region, solidifying its market dominance.

How Is the Increasing Demand for Advanced Research In the Asia-Pacific Region Influencing The Fetal Bovine Serum (FBS) Market?

The Asia-Pacific region is anticipated to experience the fastest growth in the Fetal Bovine Serum (FBS), driven by the increasing demand for advanced research and therapeutic applications in various medical fields. As countries like China, Japan, and India invest significantly in healthcare infrastructure and biotechnology research, the need for effective and innovative treatment options is rising. Cryotherapy, recognized for its efficacy in pain management, muscle recovery, and rehabilitation, aligns perfectly with this growing focus on cutting-edge medical solutions.

The region is witnessing a surge in health consciousness among its population, prompting a rise in demand for non-invasive therapies. This trend is further supported by an increase in fitness and wellness facilities that utilize cryotherapy as part of their recovery programs. Moreover, favorable government policies promoting healthcare advancements and investments in medical technologies are expected to fuel market growth. The combination of growing awareness, rising healthcare expenditures, and a robust research environment position the Asia-Pacific region as a key player in the global cryotherapy market, promising a prosperous future for cryotherapy technologies and services.

Competitive Landscape

The competitive landscape of the Fetal Bovine Serum Market is dynamic and constantly evolving. New players are entering the market, and existing players are investing in research and development to maintain their competitive edge. The market is characterized by intense competition, rapid technological advancements, and a growing demand for innovative and efficient solutions.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the fetal bovine serum market include:

• Thermo Fisher Scientific
• Merck KGaA
• AGE Healthcare
• Atlanta Biologicals
• Bovogen Biologicals
• PAN-Biotech
• Biological Industries
• Corning Life Sciences
• Wisent Inc.
• MBIO
• Fetal Bovine Serum Latest Developments
• In January 2024, PixelRo, a spin-off from Samsung Electronics' internal venture fostering program C Lab, will prepare for the CES 2024. At the occasion, the company intends to reveal its groundbreaking innovations that are transforming the digital eye care industry.
• In January 2024, Aleph Farms, an Israeli meat manufacturer, reached a historic milestone when it received the world's first regulatory certification for cell-cultured beef. This accomplishment signifies a watershed moment in the alternative protein industry.
• In August 2023, Omeat, a pioneering cultured meat company that emerged from stealth mode, will reveal its unique and slaughter-free approach to the public. Currently, it is one of the first revenue-generating cultured meat firms.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Fetal Bovine Serum Market, By Application

• Biopharmaceutical Industry
• Academic & Research Facilities
• Cell Therapy & Tissue Engineering

5. Fetal Bovine Serum Market, By End User

• Commercial firms
• Contract Research Organizations (CROs)
• Academic & Research Facilities

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Thermo Fisher Scientific
• Merck KGaA
• GE Healthcare
• Atlanta Biologicals
• Bovogen Biologicals
• PAN-Biotech
• Biological Industries
• Corning Life Sciences
• Wisent Inc.
• RMBIO

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References